Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2014 by Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor:
Collaborator:
H. Lundbeck A/S
Information provided by (Responsible Party):
Otsuka Pharmaceutical Development & Commercialization, Inc.
ClinicalTrials.gov Identifier:
NCT01567527
First received: March 26, 2012
Last updated: April 11, 2014
Last verified: April 2014

March 26, 2012
April 11, 2014
August 2012
February 2016   (final data collection date for primary outcome measure)
Time from randomization to recurrence of any mood episode during Double-Bind Placebo Controlled phase [ Time Frame: Up to 52 weeks from randomization ] [ Designated as safety issue: No ]
Efficacy evaluations will be assessed using the following instruments: YMRS, MADRS, CGI-BP-S, and CGI-BP Change from Preceding Phase.
Time from randomization to recurrence of any mood episode during Double-Bind Placebo Controlled phase [ Time Frame: 52 Weeks ] [ Designated as safety issue: No ]
Efficacy evaluations will be assessed using the following instruments: YMRS, MADRS, CGI-BP-S, and CGI-BP Change from Preceding Phase.
Complete list of historical versions of study NCT01567527 on ClinicalTrials.gov Archive Site
  • Proportion of subjects meeting criteria for recurrence of any mood episode(manic, mixed, depressive) [ Time Frame: Up to 52 weeks from randomization ] [ Designated as safety issue: No ]
  • Mean change from randomization to endpoint in the CGI-BP-S (mania) score [ Time Frame: Up to 52 weeks from randomization ] [ Designated as safety issue: No ]
  • Time from randomization to recurrence defined by hospitalization for a mood episode. [ Time Frame: Up to 52 weeks from randomization ] [ Designated as safety issue: No ]
  • Proportion of subjects meeting criteria for recurrence of any mood episode(manic, mixed, depressive) [ Time Frame: 52 Weeks ] [ Designated as safety issue: No ]
  • Mean change from randomization to endpoint in the CGI-BP-S (mania) score [ Time Frame: 52 Weeks ] [ Designated as safety issue: No ]
  • Time from randomization to recurrence defined by hospitalization for a mood episode. [ Time Frame: 52 Weeks ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients
52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder

This will be a randomized, double-blind, placebo-controlled trial to assess the time to recurrence of any mood episode in subjects with bipolar I disorder who have maintained stability on aripiprazole IM depot for at least 8 weeks. This trial will include male and female subjects 18 to 65 years of age, inclusive, with a diagnosis of bipolar I disorder, according to DSM-IV-TR criteria and confirmed by the Mini International Neuropsychiatric Interview (MINI), who have experienced at least one previous manic episode of sufficient severity to require hospitalization and/or treatment with a mood stabilizer or antipsychotic agent in addition to their current manic episode. All subjects must be experiencing a manic episode (per DSM-IV-TR criteria) with a YMRS total score ≥ 20 at trial entry. Both inpatients and outpatients are eligible for this trial.

This trial will consist of a screening phase followed by 4 treatment phases. Subjects will undergo screening for eligibility, followed by a conversion to oral aripiprazole monotherapy phase, if needed, an oral aripiprazole stabilization phase, a single-blind aripiprazole IM depot stabilization phase, and, a double-blind, placebo-controlled phase.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Bipolar I Disorder
  • Drug: Intramuscular (IM) Depot Aripiprazole
    Formulation: Intramuscular (IM) Depot Aripiprazole Formulation 400 mg or 300 mg, once a month injection
  • Drug: Intramuscular (IM) Depot Placebo
    Formulation: Intramuscular (IM) Depot Placebo 400 mg or 300 mg, once a month injection
  • Active Comparator: 1
    Active Comparator: Treatment of Aripiprazole IM Depot
    Intervention: Drug: Intramuscular (IM) Depot Aripiprazole
  • Placebo Comparator: 2
    Placebo Comparator: Treatment of IM Depot Placebo
    Intervention: Drug: Intramuscular (IM) Depot Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
688
February 2016
February 2016   (final data collection date for primary outcome measure)

Key Inclusion Criteria:

  1. Male and female subjects 18 to 65 years of age, inclusive, at time of informed consent.
  2. Subjects with a current diagnosis of bipolar I disorder, as defined by DSM-IV-TR criteria and confirmed by the MINI and a history of at least one previous manic or mixed episode with manic symptoms of sufficient severity to require one of the following interventions: hospitalization and/or treatment with a mood stabilizer, and/or treatment with an antipsychotic agent, in addition to their current manic episode. "Require" is defined as an intervention that occurred rather than one that was recommended. Rapid cyclers with 8 or fewer episodes in the previous year will be included.
  3. Subjects currently experiencing a manic episode with a YMRS total score of ≥20 at the Screening Visit.
  4. Subjects can have an inpatient or outpatient status prior to entry into Phase C (IM depot stabilization).
  5. In the investigator's opinion, subjects who are able to understand the nature of the trial and follow protocol requirements, including the prescribed dosage regimens, tablet ingestion, aripiprazole IM depot injection, and discontinuation of prohibited concomitant medications; who can read and understand the written word in order to complete subject-reported outcomes measures; and who can be reliably rated on assessment scales.

Key Exclusion Criteria:

  1. Subjects with a current Axis I (DSM-IV-TR) diagnosis other than bipolar I disorder.
  2. Subjects who have NOT experienced at least one previous manic or mixed episode with manic symptoms of sufficient severity to require one of the following interventions: hospitalization and/or treatment with a mood stabilizer, and /or treatment with an antipsychotic agent, excluding their current manic episode. "Require" is defined as a intervention that occurred rather than one that was recommended.
  3. Subjects with bipolar I disorder who are considered resistant/refractory to treatment for manic symptoms by history.
  4. Subjects unresponsive to clozapine for treatment of mania.
  5. Subjects with a significant risk of committing suicide based on history, mental status examination, investigator's judgment, or C-SSRS answer of "yes" to question 4 or 5 (current or within the last 90 days).
  6. Subjects with a current manic episode with a duration of > 2 years.
  7. Subjects who currently (within the past month) meet DSM-IV-TR criteria for substance abuse or substance dependence; this includes the abuse of alcohol and benzodiazepines, but excludes the use of caffeine and/or nicotine.
  8. Subjects who have a history or evidence of a medical condition that would expose them to an undue risk of a significant adverse event (AE) or interfere with assessments of safety or efficacy during the course of the trial, including but not limited to hepatic, renal, respiratory, cardiovascular, endocrine, neurologic, hematologic, or immunologic disease as determined by the clinical judgment of the investigator.
  9. Subjects who are currently experiencing a mixed or a depressive episode (per DSM-IV-TR criteria).
  10. Subjects with a history of hypersensitivity to antipsychotic agents.
Both
18 Years to 65 Years
No
Contact: INC Research sm_opdc.ctgov@incresearch.com
United States,   Canada,   Japan,   Korea, Republic of,   Poland,   Romania,   Taiwan
 
NCT01567527
31-08-250
Yes
Otsuka Pharmaceutical Development & Commercialization, Inc.
Otsuka Pharmaceutical Development & Commercialization, Inc.
H. Lundbeck A/S
Study Director: Stacy Wu, MD Otsuka Pharmaceutical Development and Commercialization, Inc.
Otsuka Pharmaceutical Development & Commercialization, Inc.
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP